Two‐year follow‐up of a randomized phase III clinical trial of nivolumab vs. the investigator's choice of therapy in the Asian population for recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141)

BACKGROUND: The present study evaluated the 2‐year survival of the Asian population in the CheckMate 141 trial. METHODS: The CheckMate 141 trial included patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). In the present study, 34 Asian patients (nivolum...

Descripción completa

Detalles Bibliográficos
Autores principales: Yen, Chia‐Jui, Kiyota, Naomi, Hanai, Nobuhiro, Takahashi, Shunji, Yokota, Tomoya, Iwae, Shigemichi, Shimizu, Yasushi, Hong, Ruey‐Long, Goto, Masahiro, Kang, Jin‐Hyoung, Li, Wing Sum Kenneth, Ferris, Robert L., Gillison, Maura, Endo, Toshimitsu, Jayaprakash, Vijayvel, Tahara, Makoto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7540331/
https://www.ncbi.nlm.nih.gov/pubmed/32583557
http://dx.doi.org/10.1002/hed.26331

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7540331/
https://www.ncbi.nlm.nih.gov/pubmed/32583557
http://dx.doi.org/10.1002/hed.26331

Ejemplares similares